Progesterone inhibits activation-induced deaminase by binding to the promoter

Journal of Immunology

Volumn 183, Issue 2, 2009, Pages 1238-1244

  Pauklin, Siim ^a   Petersen Mahrt, Svend K ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROGESTERONE; PROGESTERONE RECEPTOR; AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE REPRESSION; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RNA SPLICING; RNA TRANSLATION; SOMATIC HYPERMUTATION; SPLEEN; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE REARRANGEMENT; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROMOTER REGION;

ANIMALS; B-LYMPHOCYTES; CYTIDINE DEAMINASE; DOWN-REGULATION; FEMALE; IMMUNOGLOBULIN CLASS SWITCHING; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PROGESTERONE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; SPLEEN; TRANSCRIPTION, GENETIC;

EID: 70249142555     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803915     Document Type: Article

References (44)

1. Neuberger, M. S., R. S. Harris, J. Di Noia, and S. K. Petersen-Mahrt. 2003. Immunity through DNA deamination. Trends Biochem. Sci. 28: 305-312.
2. Muramatsu, M., V. S. Sankaranand, S. Anant, M. Sugai, K. Kinoshita, N. O. Davidson, and T. Honjo. 1999. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274: 18470-18476.
3. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
4. Arakawa, H., J. Hauschild, and J. M. Buerstedde. 2002. Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 295: 1301-1306.
5. Harris, R. S., J. E. Sale, S. K. Petersen-Mahrt, and M. S. Neuberger. 2002. AID is essential for immunoglobulin V gene conversion in a cultured B cell line. Curr. Biol. 12: 435-438.
6. Rabbitts, T. H., P. H. Hamlyn, and R. Baer. 1983. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 306: 760-765. (Pubitemid 14206039)
7. Rabbitts, T. H., A. Forster, P. Hamlyn, and R. Baer. 1984. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma. Nature 309: 592-597. (Pubitemid 14106438)
8. Muschen, M., D. Re, B. Jungnickel, V. Diehl, K. Rajewsky, and R. Kuppers. 2000. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J. Exp. Med. 192: 1833-1840.
9. Kuppers, R., and R. Dalla-Favera. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580-5594.
10. Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S. Chaganti, R. Kuppers, and R. Dalla-Favera. 2001. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341-346.
11. Ramiro, A. R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Chen-Kiang, M. Muramatsu, T. Honjo, A. Nussenzweig, and M. C. Nussenzweig. 2004. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118: 431-438.
12. Bombardieri, M., F. Barone, F. Humby, S. Kelly, M. McGurk, P. Morgan, S. Challacombe, S. De Vita, G. Valesini, J. Spencer, and C. Pitzalis. 2007. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J. Immunol. 179: 4929-4938.
13. Hsu, H. C., Y. Wu, P. Yang, Q. Wu, G. Job, J. Chen, J. Wang, M. A. Accavitti-Loper, W. E. Grizzle, R. H. Carter, and J. D. Mountz. 2007. Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J. Immunol. 178: 5357-5365.
14. Jiang, C., J. Foley, N. Clayton, G. Kissling, M. Jokinen, R. Herbert, and M. Diaz. 2007. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol. 178: 7422-7431.
15. Okazaki, I. M., H. Hiai, N. Kakazu, S. Yamada, M. Muramatsu, K. Kinoshita, and T. Honjo. 2003. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197: 1173-1181.
16. Endo, Y., H. Marusawa, K. Kinoshita, T. Morisawa, T. Sakurai, I. M. Okazaki, K. Watashi, K. Shimotohno, T. Honjo, and T. Chiba. 2007. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-κB signaling. Oncogene 26: 5587-5595. (Pubitemid 47267836)
17. Matsumoto, Y., H. Marusawa, K. Kinoshita, Y. Endo, T. Kou, T. Morisawa, T. Azuma, I. M. Okazaki, T. Honjo, and T. Chiba. 2007. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 13: 470-476.
18. Sayegh, C. E., M. W. Quong, Y. Agata, and C. Murre. 2003. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat. Immunol. 4: 586-593.
19. Dedeoglu, F., B. Horwitz, J. Chaudhuri, F. W. Alt, and R. S. Geha. 2004. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NF-κB. Int. Immunol. 16: 395-404.
20. Gonda, H., M. Sugai, Y. Nambu, T. Katakai, Y. Agata, K. J. Mori, Y. Yokota, and A. Shimizu. 2003. The balance between Pax5 and Id2 activities is the key to AID gene expression. J. Exp. Med. 198: 1427-1437.
21. Cohen-Solal, J. F., V. Jeganathan, C. M. Grimaldi, E. Peeva, and B. Diamond. 2006. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 305: 67-88.
22. Nalbandian, G., and S. Kovats. 2005. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol. Res. 31: 91-106.
23. Peeva, E., and M. Zouali. 2005. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol. Lett. 101: 123-143.
24. Roy, D., and J. G. Liehr. 1999. Estrogen, DNA damage and mutations. Mut. Res. 424: 107-115.
25. Pauklin, S., I. V. Sernandez, G. Bachmann, A. R. Ramiro, and S. K. Petersen-Mahrt. 2009. Estrogen directly activates AID transcription and function. J. Exp. Med. 206: 99-111.
26. Kastner, P., A. Krust, B. Turcotte, U. Stropp, L. Tora, H. Gronemeyer, and P. Chambon. 1990. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9: 1603-1614.
27. Kinoshita, K., M. Harigai, S. Fagarasan, M. Muramatsu, and T. Honjo. 2001. A hallmark of active class switch recombination: transcripts directed by I promoters on looped-out circular DNAs. Proc. Natl. Acad. Sci. USA 98: 12620-12623.
28. Lumsden, J. M., T. McCarty, L. K. Petiniot, R. Shen, C. Barlow, T. A. Wynn, H. C. Morse, 3rd, P. J. Gearhart, A. Wynshaw-Boris, E. E. Max, and R. J. Hodes. 2004. Immunoglobulin class switch recombination is impaired in Atm-deficient mice. J. Exp. Med. 200: 1111-1121.
29. Reina-San-Martin, B., S. Difilippantonio, L. Hanitsch, R. F. Masilamani, A. Nussenzweig, and M. C. Nussenzweig. 2003. H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. J. Exp. Med. 197: 1767-1778.
30. Sale, J. E., and M. S. Neuberger. 1998. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 9: 859-869.
31. Martin, A., P. D. Bardwell, C. J. Woo, M. Fan, M. J. Shulman, and M. D. Scharff. 2002. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 415: 802-806.
32. -/- mice. J. Exp. Med. 203: 2085-2094.
33. Liu, M., J. L. Duke, D. J. Richter, C. G. Vinuesa, C. C. Goodnow, S. H. Kleinstein, and D. G. Schatz. 2008. Two levels of protection for the B cell genome during somatic hypermutation. Nature 451: 841-845.
34. Roubinian, J. R., N. Talal, J. S. Greenspan, J. R. Goodman, and P. K. Siiteri. 1978. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J. Exp. Med. 147: 1568-1583.
35. 1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 62: 341-346.
36. Savouret, J. F., A. Bailly, M. Misrahi, C. Rauch, G. Redeuilh, A. Chauchereau, and E. Milgrom. 1991. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J. 10: 1875-1883.
37. Conticello, S. G., C. J. Thomas, S. K. Petersen-Mahrt, and M. S. Neuberger. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22: 367-377.
38. Dorsett, Y., K. M. McBride, M. Jankovic, A. Gazumyan, T. H. Thai, D. F. Robbiani, M. Di Virgilio, B. R. San-Martin, G. Heidkamp, T. A. Schwickert, et al. 2008. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28: 630-638.
39. Takizawa, M., H. Tolarova, Z. Li, W. Dubois, S. Lim, E. Callen, S. Franco, M. Mosaico, L. Feigenbaum, F. W. Alt, A. Nussenzweig, M. Potter, and R. Casellas. 2008. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205: 1949-1957.
40. Teng, G., P. Hakimpour, P. Landgraf, A. Rice, T. Tuschl, R. Casellas, and F. N. Papavasiliou. 2008. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28: 621-629.
41. Beral, V. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427.
42. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288: 321-333.
43. Caufriez, A. 2007. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. Annales d'endocrinologie. 68: 241-250.
44. Wang, Q., X. Li, L. Wang, Y. H. Feng, R. Zeng, and G. Gorodeski. 2004. Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 145: 5568-5579.